B型肝炎ウイルス(Hepatitis B):世界の治験レビュー(2014年下半期版)

◆英語タイトル:Hepatitis B Global Clinical Trials Review, H2, 2014
◆商品コード:GDHC2439CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年11月28日
◆ページ数:134
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるB型肝炎ウイルス(Hepatitis B) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - B型肝炎ウイルス(Hepatitis B)
  - 当レポートの概要
・B型肝炎ウイルス(Hepatitis B):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Hepatitis B Global Clinical Trials Review, H2, 2014

Summary

GlobalData’s clinical trial report, “Hepatitis B Global Clinical Trials Review, H2, 2014″ provides data on the Hepatitis B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis B. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Hepatitis B 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Hepatitis B 25
Subjects Recruited Over a Period of Time 33
Clinical Trials by Sponsor Type 34
Prominent Sponsors 35
Top Companies Participating in Hepatitis B Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Hepatitis B 39
Nov 10, 2014: TetraLogic Pharmaceuticals Announces Results Of Preclinical Studies In Hepatitis B 39
Nov 10, 2014: Novira Therapeutics Announces Presentation of Phase 1a Safety and Pharmacokinetic Data for NVR 3-778 39
Nov 10, 2014: Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B 40
Oct 21, 2014: Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta 40
Oct 15, 2014: Tekmira Presents Results Of Preclinical Studies With Hepatitis B Therapeutic 41
Oct 09, 2014: Tekmira to Present HBV Pre-Clinical Data at Meeting of the Oligonucleotide Therapeutics Society 41
Oct 08, 2014: Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting 2014 42
Oct 07, 2014: REPLICor to Present Updated Clinical Trial Data of REP-9-AC at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 42
Oct 01, 2014: REPLICor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys in patients with hepatitis B / hepatitis D co-infection 43
Sep 25, 2014: Radiant Research/Clinical Research Advantage Enrolls More Than 8,000 Subjects for Hepatitis B Vaccine Study 43
Sep 22, 2014: Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B 44
Sep 04, 2014: Novira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies 44
Aug 27, 2014: TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses 45
Aug 27, 2014: Green Cross Initiates Phase II Trial of Investigational Recombinant Hepatitis B Immune Globulin 45
Clinical Trial Profiles 46
Clinical Trial Overview of Top Companies 46
GlaxoSmithKline plc 46
Clinical Trial Overview of GlaxoSmithKline plc 46
Gilead Sciences, Inc. 57
Clinical Trial Overview of Gilead Sciences, Inc. 57
F. Hoffmann-La Roche Ltd. 63
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 63
Merck & Co., Inc. 68
Clinical Trial Overview of Merck & Co., Inc. 68
Bristol-Myers Squibb Company 71
Clinical Trial Overview of Bristol-Myers Squibb Company 71
Novartis AG 74
Clinical Trial Overview of Novartis AG 74
Sanofi 77
Clinical Trial Overview of Sanofi 77
Bukwang Pharm.Co., Ltd. 80
Clinical Trial Overview of Bukwang Pharm.Co., Ltd. 80
Dynavax Technologies Corporation 82
Clinical Trial Overview of Dynavax Technologies Corporation 82
LG Life Sciences, Ltd. 83
Clinical Trial Overview of LG Life Sciences, Ltd. 83
Clinical Trial Overview of Top Institutes / Government 84
National Taiwan University Hospital 84
Clinical Trial Overview of National Taiwan University Hospital 84
The National Institute of Diabetes and Digestive and Kidney Diseases 86
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 86
The National Institute of Allergy and Infectious Diseases 87
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 87
Sun Yat-sen University 88
Clinical Trial Overview of Sun Yat-sen University 88
Third Affiliated Hospital of Sun Yat-sen University 89
Clinical Trial Overview of Third Affiliated Hospital of Sun Yat-sen University 89
Yonsei University 90
Clinical Trial Overview of Yonsei University 90
The Foundation for Liver Research 91
Clinical Trial Overview of The Foundation for Liver Research 91
Chinese University of Hong Kong 92
Clinical Trial Overview of Chinese University of Hong Kong 92
The University of Hong Kong 93
Clinical Trial Overview of The University of Hong Kong 93
French National Agency for Research on AIDS and Viral Hepatitis 94
Clinical Trial Overview of French National Agency for Research on AIDS and Viral Hepatitis 94
Five Key Clinical Profiles 95
Appendix 132
Abbreviations 132
Definitions 132
Research Methodology 133
Secondary Research 133
About GlobalData 134
Contact Us 134
Disclaimer 134
Source 134

List of Tables
Hepatitis B Therapeutics, Global, Clinical Trials by Region, 2014* 7
Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Hepatitis B Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Hepatitis B Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Hepatitis B Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Hepatitis B Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 33
Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 34
Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 35
Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 37
Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 38
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 46
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 57
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 63
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 68
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 71
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 74
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 77
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Bukwang Pharm.Co., Ltd., 2014* 80
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Dynavax Technologies Corporation, 2014* 82
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by LG Life Sciences, Ltd., 2014* 83
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 84
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014* 86
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 87
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 88
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Affiliated Hospital of Sun Yat-sen University, 2014* 89
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 90
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The Foundation for Liver Research, 2014* 91
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by Chinese University of Hong Kong, 2014* 92
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2014* 93
Hepatitis B Therapeutics Clinical Trials Market, Global, Clinical Trials by French National Agency for Research on AIDS and Viral Hepatitis, 2014* 94

List of Figures
Hepatitis B Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Hepatitis B Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hepatitis B Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Hepatitis B Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Hepatitis B Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Hepatitis B Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Hepatitis B Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Hepatitis B to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hepatitis B Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hepatitis B to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hepatitis B Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Hepatitis B Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Hepatitis B Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Hepatitis B Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Hepatitis B Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 33
Hepatitis B Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 34
Hepatitis B Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 35
Hepatitis B Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 36
Hepatitis B Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 38
GlobalData Methodology 133

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[B型肝炎ウイルス(Hepatitis B):世界の治験レビュー(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆